POLB 001 patent portfolio strengthened through granting of US patent
POLB 001 patent portfolio strengthened through granting of US patent
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
Early data readout indicates a successful LPS human challenge trial
Continued expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline